XML 52 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The Company’s revenue by product line, and related approximate percentage of total sales for 2024, 2023 and 2022 were as follows:

Twelve Months Ended December 31, 2024 and 2023
202420232022
Nylon$348,501 23%$356,632 23%$485,241 25%
Caprolactam276,303 18%298,375 20%319,863 16%
Plant Nutrients*458,152 30%477,929 31%657,984 34%
Chemical Intermediates*434,601 29%400,663 26%482,552 25%
$1,517,557 100%$1,533,599 100%$1,945,640 100%
* The Company transferred certain products between its Chemical Intermediates product line and its Plant Nutrients product line to align more closely with its current sales structure. Historical information has been reclassified to reflect these changes for all periods presented in the Consolidated Financial Statements. Total revenue amounts were not impacted for either period.

The Company’s revenues by geographic area, and related approximate percentage of total sales for 2024, 2023 and 2022 were as follows:

Twelve Months Ended December 31, 2024 and 2023
202420232022
United States$1,304,971 86 %$1,250,094 82 %$1,622,537 83 %
International212,586 14 %283,505 18 %323,103 17 %
Total$1,517,557 100 %$1,533,599 100 %$1,945,640 100 %
Schedule of Deferred Income and Customer Advances Below is a roll-forward of Deferred income and customer advances for the twelve months ended December 31, 2024:
Deferred Income and Customer Advances2024
Opening balance January 1, 2024$15,678 
Additional cash advances37,954 
Less amounts recognized in revenues(16,094)
Ending balance December 31, 2024$37,538